Aerie Pharmaceuticals reported $39.44M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Aerie Pharmaceuticals AERI:US $ 39.44M 17M
Alimera Sciences ALIM:US $ 7.86M 2.09M
Amarin AMRN:US $ 228M 8.85M
Bluebird Bio BLUE:US $ 81.5M 24.76M
Cara Therapeutics CARA:US $ 46.72M 25.36M
Coherus Biosciences CHRS:US $ 275.48M 50.2M
Endo International Ordinary Shares ENDP:US $ 1191.57M 221.58M
Horizon Pharma HZNP:US $ 1892.56M 249.43M
Insmed INSM:US $ 416.08M 99.63M
Mirati Therapeutics MRTX:US $ 245.51M 47.91M
Novartis NOVN:VX SF 3625M 10227M
Ophthotech OPHT:US $ 141.11M 50.75M
Pacira Pharmaceuticals PCRX:US $ 122.06M 104.69M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M
Revance Therapeutics RVNC:US $ 69.42M 128.94M
Supernus Pharmaceuticals SUPN:US $ 173.43M 57.71M
Teva Pharmaceutical Industries TEVA:US $ 2058M 117M
Valeant Pharmaceuticals VRX:CN $ 848.26M 400.74M
Zoetis ZTS:US $ 2648M 484M